NeuroMetrix Ships 500th Medical Device For Detecting Nerve Damage in Diabetics

  NeuroMetrix Ships 500th Medical Device For Detecting Nerve Damage in
  Diabetics

           NC-stat^® DPNCheck^™ device addresses unmet medical need

Business Wire

WALTHAM, Mass. -- May 24, 2012

NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device
company focused on the diagnosis and treatment of the neurological
complications of diabetes, today announced that it shipped its 500^th
NC-stat^® DPNCheck^™ device. NC-stat DPNCheck is a fast, accurate and
quantitative point-of-care test for the evaluation of systemic neuropathies
such as diabetic peripheral neuropathy (DPN). DPN affects more than half of
people with diabetes and may lead to foot ulcers and limb amputation, as well
as pain and an overall reduction in quality of life.

Dr. Shai Gozani performs a NC-stat DPNCheck test used to evaluate diabetic
peripheral neuropathy. (P ...

Dr. Shai Gozani performs a NC-stat DPNCheck test used to evaluate diabetic
peripheral neuropathy. (Photo: Business Wire)

“The placement of 1,000 NC-stat DPNCheck devices is one of our important 2012
goals and we have reached the half-way point ahead of plan,” said Shai N.
Gozani M.D., Ph.D., President and Chief Executive Officer. “Most encouraging
has been the interest level we’ve seen in our various markets including
managed care, endocrinology and podiatry clinics, and in the retail health
sector. All of these markets recognize the value of early and accurate
identification of DPN leading to opportunities for intervention ultimately
resulting in improved patient care and lower costs.”

About NeuroMetrix

NeuroMetrix is an innovative medical device company that develops and markets
home use and point-of-care devices, associated consumables, and support
software for the treatment and management of diabetes and its complications.
The company is focused on nerve related complications of diabetes, called
diabetic neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation, cause disabling pain, and increase the risk of falling in the
elderly. The annual cost of diabetic neuropathies has been estimated at $14
billion in the United States. The company’s products are used by physicians
and other clinicians, in retail health settings such as pharmacies, and by
managed care organizations to optimize patient care and reduce healthcare
costs. The company markets the NC-stat^® DPNCheck^™ device, which is a rapid,
accurate, and quantitative point-of-care test for diabetic neuropathy. This
product is used to detect diabetic neuropathy at an early stage and to guide
treatment. The company is in late stage development of SENSUS^™, a pain
management device that will be used to treat painful diabetic neuropathy, a
form of chronic intractable pain. Currently, painful diabetic neuropathy is
treated pharmacologically, which is a $2 billion annual market. The company
has additional therapeutic products in its pipeline. For more information,
please visit http://www.neurometrix.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50289368&lang=en

Multimedia Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50289368
〈=en

Contact:

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
neurometrix.ir@neurometrix.com